HSBC Holdings
KZIA

HSBC Holdings’s Kazia Therapeutics KZIA Stock Holding History

HSBC Holdings’s Portfolio KZIA Stock Details KZIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,279
Closed -$20.1K – 3076
2024
Q1 		$20.1K Sell
1,279
-725
-36% -$10.9K ﹤0.01% 2994
2023
Q4 		$45.1K Buy
+2,004
New +$58.7K ﹤0.01% 2657

Other funds holding KZIA

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $2.19B AUM 21.28% 1-Year Est. Return

HSBC Holdings's KZIA Position: Q2 2024 in Review

HSBC Holdings sold out of Kazia Therapeutics (KZIA) in Q2 2024, closing a stake of 1,279 shares — an estimated $20.1K sold.

HSBC Holdings first reported a position in KZIA in Q4 2023 and held it in 2 quarters. The position peaked at $45.1K in Q4 2023. 9 funds tracked by Wall St. Rank hold KZIA as of Q2 2024.

  • HSBC Holdings reported no remaining Kazia Therapeutics position as of Q2 2024 after selling out during the quarter.
  • HSBC Holdings sold 1,279 Kazia Therapeutics shares in Q2 2024, an estimated $20.1K.
  • HSBC Holdings first reported a position in Kazia Therapeutics in Q4 2023 and held it in 2 quarters.
  • HSBC Holdings's Kazia Therapeutics position peaked at $45.1K in Q4 2023.
  • 9 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q2 2024.

Based on HSBC Holdings's 13F filing for Q2 2024, filed 12 Aug 2024.